2-benzyl-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde | 1175882-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-benzyl-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde
• 英文别名: 2-benzyl-5-formyl-6-(4'-fluorophenyl)-imidazo[2,1-b][1,3,4]thiadiazole
• CAS: 1175882-77-5
• 化学式: C₁₈H₁₂FN₃OS
• 分子量: 337.377
• InChiKey: QGBYCVOQHKEDHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  75.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-吲哚酮 、 2-benzyl-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde 在 哌啶 作用下， 以 甲醇 为溶剂， 以82%的产率得到3-((2-benzyl-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-methylidene)-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain

  摘要：

  The antiapoptotic protein BCL2 is overexpressed in several cancers and contributes to prolonged cell survival and chemoresistance, lending itself as an excellent target for cancer therapy. Here, we report the design, synthesis, and characterization of Disarib, a novel BCL2 inhibitor. Disarib showed selective cytotoxicity in BCL2 high cancer cell lines, and CLL patient primary cells, as compared to BCL2 low cell lines. BCL2 knockdown in cells rendered remarkable resistance to Disarib, while sensitivity was regained upon its ectopic expression, establishing target specificity. In silico, biochemical and biophysical studies demonstrated strong affinity of Disarib to BCL2, but not to other antiapoptotic BCL2 family members viz., BCL‐xL, BCL2A1 etc. Interestingly, biophysical studies showed that BH1 domain deletion mutant demonstrated ~ 67‐fold reduction in BCL2‐Disarib interaction, while it was only ~ 20‐fold in the case of BH3 deletion mutant, suggesting predominant involvement of the BH1 domain for Disarib binding. Thus, we report identification of a novel BCL2 inhibitor with a unique mechanism of BCL2 inhibition, as opposed to the well‐studied BH3 domain targeting.

  DOI：

  10.1111/febs.13815
• 作为产物：
  描述：

  5-苄基-[1,3,4]噁二唑-2-胺 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 2-benzyl-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde
  参考文献：
  名称：

  新型2-芳烷基-5-取代-6-（4'-氟苯基）-咪唑并[2,1-b] [1,3,4]噻二唑衍生物的合成及生物学评价

  摘要：

  咪唑并[2,1-b]噻唑衍生物左旋咪唑据报道是潜在的抗肿瘤药。在本研究中，我们合成，表征和评估了其新类似物的化学活性，这些新类似物在芳烷基中和具有相同化学主链但侧链不同的咪唑并噻二唑分子即2-芳烷基-6-（4'-氟苯基）-咪唑上具有取代作用[2,1-b] [1,3,4]噻二唑（SCR1），2-芳烷基-5-溴-6-（4'-氟苯基）-咪唑[2,1-b] [1,3,4 ]-噻二唑（SCR2），2-芳烷基-5-甲酰基-6-（4'-氟苯基）-咪唑[2,1-b] [1,3,4]-噻二唑（SCR3）和2-芳烷基-5 -白血病细胞上的-thiocyanato-6-（4'-氟苯基）-咪唑并[2,1-b] [1,3,4]-噻二唑（SCR4）。细胞毒性研究表明3a，4a和4c表现出很强的细胞毒性，而其他的则具有中等的细胞毒性。在这些我们选择了图4a（IC 50，μM8）为理解它的细胞毒性的机制。FACS分析结合

  DOI：

  10.1016/j.ejmech.2011.02.064

文献信息

• Kumar, Sujeet; Metikurki, Basavaraj; Bhadauria, Vivek Singh, Acta poloniae pharmaceutica, 2016, vol. 73, # 4, p. 913 - 929
  作者：Kumar, Sujeet、Metikurki, Basavaraj、Bhadauria, Vivek Singh、De Clercq, Erik、Schols, Dominique、Tokuda, Harukuni、Karki, Subhas S.

  DOI：——

  日期：——
• Synthesis and biological evaluation of novel 2-aralkyl-5-substituted-6-(4′-fluorophenyl)-imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent anticancer agents
  作者：Subhas S. Karki、Kuppusamy Panjamurthy、Sujeet Kumar、Mridula Nambiar、Sureshbabu A. Ramareddy、Kishore K. Chiruvella、Sathees C. Raghavan

  DOI：10.1016/j.ejmech.2011.02.064

  日期：2011.6

  Levamisole, the imidazo[2,1-b]thiazole derivative has been reported as a potential antitumor agent. In the present study, we synthesized, characterized and evaluated biological activity of its novel analogues with substitution in the aralkyl group and on imidazothiadiazole molecules with same chemical backbone but different side chains namely 2-aralkyl-6-(4′-fluorophenyl)-imidazo[2,1-b][1,3,4]thiadiazoles

  咪唑并[2,1-b]噻唑衍生物左旋咪唑据报道是潜在的抗肿瘤药。在本研究中，我们合成，表征和评估了其新类似物的化学活性，这些新类似物在芳烷基中和具有相同化学主链但侧链不同的咪唑并噻二唑分子即2-芳烷基-6-（4'-氟苯基）-咪唑上具有取代作用[2,1-b] [1,3,4]噻二唑（SCR1），2-芳烷基-5-溴-6-（4'-氟苯基）-咪唑[2,1-b] [1,3,4 ]-噻二唑（SCR2），2-芳烷基-5-甲酰基-6-（4'-氟苯基）-咪唑[2,1-b] [1,3,4]-噻二唑（SCR3）和2-芳烷基-5 -白血病细胞上的-thiocyanato-6-（4'-氟苯基）-咪唑并[2,1-b] [1,3,4]-噻二唑（SCR4）。细胞毒性研究表明3a，4a和4c表现出很强的细胞毒性，而其他的则具有中等的细胞毒性。在这些我们选择了图4a（IC 50，μM8）为理解它的细胞毒性的机制。FACS分析结合
• Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain
  作者：Divyaanka Iyer、Supriya V. Vartak、Archita Mishra、Gunaseelan Goldsmith、Sujeet Kumar、Mrinal Srivastava、Mahesh Hegde、Vidya Gopalakrishnan、Mark Glenn、Mahesh Velusamy、Bibha Choudhary、Nagesh Kalakonda、Subhas S. Karki、Avadhesha Surolia、Sathees C. Raghavan

  DOI：10.1111/febs.13815

  日期：2016.9

  The antiapoptotic protein BCL2 is overexpressed in several cancers and contributes to prolonged cell survival and chemoresistance, lending itself as an excellent target for cancer therapy. Here, we report the design, synthesis, and characterization of Disarib, a novel BCL2 inhibitor. Disarib showed selective cytotoxicity in BCL2 high cancer cell lines, and CLL patient primary cells, as compared to BCL2 low cell lines. BCL2 knockdown in cells rendered remarkable resistance to Disarib, while sensitivity was regained upon its ectopic expression, establishing target specificity. In silico, biochemical and biophysical studies demonstrated strong affinity of Disarib to BCL2, but not to other antiapoptotic BCL2 family members viz., BCL‐xL, BCL2A1 etc. Interestingly, biophysical studies showed that BH1 domain deletion mutant demonstrated ~ 67‐fold reduction in BCL2‐Disarib interaction, while it was only ~ 20‐fold in the case of BH3 deletion mutant, suggesting predominant involvement of the BH1 domain for Disarib binding. Thus, we report identification of a novel BCL2 inhibitor with a unique mechanism of BCL2 inhibition, as opposed to the well‐studied BH3 domain targeting.